{"id":34784,"date":"2015-04-20T09:42:37","date_gmt":"2015-04-20T13:42:37","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=34784"},"modified":"2015-04-20T09:42:37","modified_gmt":"2015-04-20T13:42:37","slug":"fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784","title":{"rendered":"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>AstraZeneca plc (ADR) (NYSE:AZN)<\/strong> promise of delivering annual revenues of $45 billion by 2023 received a major boost after its lung cancer drug impressed in a phase II study against Clovis. The drug was found to extend the survival rate of patients by more than a year an indication that it can be used as a key remedy for lung cancer. AZD9291 was found to charter a median free survival of 13.5 months.<\/p>\n<p style=\"text-align: justify;\">Nearly 300 patients had been enrolled in the Phase II study toppling the 9.6 month progression-free survival rate that was posted last fall. A 54% response rate complimented with a median duration of 12.4 months positions it as a possible treatment for lung cancer.<\/p>\n<p style=\"text-align: justify;\">The pill should enable AstraZeneca plc (ADR) (NYSE:AZN) to compete better with Clovis Oncology lung cancer drug, which has a 10.4 months PFS rate. Analysts continue to call pharmaceutical companies to develop drugs with a PFS rate of more than a year.<\/p>\n<p style=\"text-align: justify;\">AstraZeneca plc (ADR) (NYSE:AZN) should enjoy an advantage in the market in terms of sales when the drug hits the market seen by Clovis sinking in the market by 4% after the announcement of a 13.5 months PFS rate. Plans are already underway to submit AZD9291 for approval by the Federal Drugs and Administration later in the next quarter.<\/p>\n<p style=\"text-align: justify;\">AstraZeneca plc (ADR) (NYSE:AZN) has also confirmed additional studies for testing in early-stage lung cancer in combination with other oncology tests. The positive findings have already caught the attention of the FDA which affirms it will accord it a speedy review as a possible treatment for lung cancer.<\/p>\n<p style=\"text-align: justify;\">AstraZeneca is already betting big on the drug upon its approval with the hope it can clock the $3 billion mark in terms of annual revenue at the back of peak expectation of $6.5 billion for PD-L1 blocking immunotherapy MEDI4736.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (ADR) (NYSE:AZN) promise of delivering annual revenues of $45 billion by 2023 received a major boost after its lung cancer drug impressed in [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":7628,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[4503,4504],"stock_ticker":[],"class_list":["post-34784","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-astrazeneca-plc-adr-nyseazn","tag-nyseazn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (ADR) (NYSE:AZN) promise of delivering annual revenues of $45 billion by 2023 received a major boost after its lung cancer drug impressed in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-04-20T13:42:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study\",\"datePublished\":\"2015-04-20T13:42:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784\"},\"wordCount\":316,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg\",\"keywords\":[\"Astrazeneca Plc (ADR) (NYSE:AZN)\",\"NYSE:AZN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784\",\"name\":\"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg\",\"datePublished\":\"2015-04-20T13:42:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784","og_locale":"en_US","og_type":"article","og_title":"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study - Wall Street PR","og_description":"AstraZeneca plc (ADR) (NYSE:AZN) promise of delivering annual revenues of $45 billion by 2023 received a major boost after its lung cancer drug impressed in [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-04-20T13:42:37+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study","datePublished":"2015-04-20T13:42:37+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784"},"wordCount":316,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg","keywords":["Astrazeneca Plc (ADR) (NYSE:AZN)","NYSE:AZN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784","url":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784","name":"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg","datePublished":"2015-04-20T13:42:37+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pg-36-east-germany-rex.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/fda-promises-speedy-review-for-astrazeneca-plc-adr-nyseazn-lung-cancer-drug-on-positive-phase-ii-study-34784#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"FDA Promises Speedy Review For AstraZeneca plc (ADR) (NYSE:AZN) Lung Cancer Drug On Positive Phase II Study"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/34784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=34784"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/34784\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7628"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=34784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=34784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=34784"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=34784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}